BRCA2 and cancer: According to the recommendations of the International Cancer of the Pancreas Screening (CAPS) Consortium summit in 2013, surveillance for the following categories is recommended: (1) individuals with PJS; (2) CDKN2A, BRCA2 or MMR gene mutation carriers with at least one affected FDR; and (3) individuals with at least two affected FDRs [74].